An overview on the role of bioactive α-glucosidase inhibitors in ameliorating diabetic complications

Hossain, Uday; Das, Abhishek; Ghosh, Sumit; Sil, Parames C.

doi:10.1016/j.fct.2020.111738

Cited by 253 publications

(151 citation statements)

References 119 publications

Supporting

Mentioning

121

Contrasting

Unclassified

Order By: Relevance

“…Alpha-glucosidase inhibitors (AGI) are a group of antidiabetic drugs whose main function is reducing carbohydrate catabolism and thus minimising glucose availability and controlling glycaemic levels [ 106 ]. One study analysed the α-glucosidase inhibitory activity of five different L. plantarum strains’ cell-free supernatants, all of which demonstrated the ability to reduce glucose degradation, especially L. plantarum CCFM0236.…”

Section: Resultsmentioning

confidence: 99%

Role of Postbiotics in Diabetes Mellitus: Current Knowledge and Future Perspectives

Cabello-Olmo

Araña

Urtasun

et al. 2021

Foods

View full text Add to dashboard Cite

In the last decade, the gastrointestinal microbiota has been recognised as being essential for health. Indeed, several publications have documented the suitability of probiotics, prebiotics, and symbiotics in the management of different diseases such as diabetes mellitus (DM). Advances in laboratory techniques have allowed the identification and characterisation of new biologically active molecules, referred to as “postbiotics”. Postbiotics are defined as functional bioactive compounds obtained from food-grade microorganisms that confer health benefits when administered in adequate amounts. They include cell structures, secreted molecules or metabolic by-products, and inanimate microorganisms. This heterogeneous group of molecules presents a broad range of mechanisms and may exhibit some advantages over traditional “biotics” such as probiotics and prebiotics. Owing to the growing incidence of DM worldwide and the implications of the microbiota in the disease progression, postbiotics appear to be good candidates as novel therapeutic targets. In the present review, we summarise the current knowledge about postbiotic compounds and their potential application in diabetes management. Additionally, we envision future perspectives on this topic. In summary, the results indicate that postbiotics hold promise as a potential novel therapeutic strategy for DM.

show abstract

Section: Resultsmentioning

confidence: 99%

Role of Postbiotics in Diabetes Mellitus: Current Knowledge and Future Perspectives

Cabello-Olmo

Araña

Urtasun

et al. 2021

Foods

View full text Add to dashboard Cite

show abstract

“…Voglibose was used to discontinue the uptake and hydrolysis of saccharides by selectively inhibiting α-glucosidase vs. pancreatic α-amylase and lactase. Miglitol, the first pseudo-monosaccharide α-glucosidase inhibitor, was approved to reduce postprandial glucose ( Hossain et al, 2020 ). However, some unexpected adverse effects (for instance, flatulence, diarrhea, and stomachache) limited their clinical application.…”

Section: Introductionmentioning

confidence: 99%

Discovery of New α-Glucosidase Inhibitors: Structure-Based Virtual Screening and Biological Evaluation

et al. 2021

View full text Add to dashboard Cite

α-Glycosidase inhibitors could inhibit the digestion of carbohydrates into glucose and promote glucose conversion, which have been used for the treatment of type 2 diabetes. In the present study, 52 candidates of α-glycosidase inhibitors were selected from commercial Specs compound library based on molecular docking–based virtual screening. Four different scaffold compounds (7, 22, 37, and 44) were identified as α-glycosidase inhibitors with IC50 values ranging from 9.99 to 35.19 μM. All these four compounds exerted better inhibitory activities than the positive control (1-deoxynojirimycin, IC50 = 52.02 μM). The fluorescence quenching study and kinetic analysis revealed that all these compounds directly bind to α-glycosidase and belonged to the noncompetitive α-glycosidase inhibitors. Then, the binding modes of these four compounds were carefully investigated. Significantly, these four compounds showed nontoxicity (IC50 > 100 μM) toward the human normal hepatocyte cell line (LO2), which indicated the potential of developing into novel candidates for type 2 diabetes treatment.

show abstract

“…The inhibition of digestive enzymes, such as α-glucosidase and α-amylase, has considerably attenuated the higher blood glucose level in diabetic conditions [ 57 , 58 ], hence the PD aqueous extract and PD-FeO NPs evaluated in vitro α-amylase and α-glucosidase enzyme inhibitory activity ( Figures S3 and S4 ). Like the antioxidant activity, PD aqueous extract (1 mg/mL) exhibited higher digestive enzyme inhibitory activity than the PD-FeO NPs (1 mg/mL).…”

Section: Resultsmentioning

confidence: 99%

Antimicrobial and Wound Healing Properties of FeO Fabricated Chitosan/PVA Nanocomposite Sponge

et al. 2021

View full text Add to dashboard Cite

Diabetic and anemia-associated diabetic wounds increase the considerable morbidity and mortality in people, as reported by clinical studies. However, no anemia-associated diabetic wound dressing materials have been developed until now. Hence, this study aimed to develop a nanocomposite scaffold composed of chitosan (CS), poly (vinyl alcohol) (PVA), and phytogenic iron oxide nanoparticles (FeO NPs), for accelerated anemia-associated diabetic wound healing. The aqueous leaves extract of Pinus densiflora (PD) was utilized for the synthesis of iron oxide nanoparticles (FeO NPs). TEM and elemental analysis confirmed smaller size PD-FeO NPs (<50 nm) synthesis with the combination of iron and oxide. In addition, in vitro biological studies displayed the moderate antioxidant, antidiabetic activities, and considerable antibacterial activity of PD-FeO NPs. Further, the different concentrations of PD-FeO NPs (0.01, 0.03, and 0.05%) incorporated CS/PVA nanocomposites sponges were developed by the freeze-drying method. The porous structured morphology and the presence of PD-FeO NPs were observed under FE-SEM. Among nanocomposite sponges, PD-FeO NPs (0.01%) incorporated CS/PVA sponges were further chosen for the in vitro wound-healing assay, based on the porous and water sorption nature. Furthermore, the in vitro wound-healing assay revealed that PD-FeO NPs (0.01%) incorporated CS/PVA has significantly increased the cell proliferation in HEK293 cells. In conclusion, the CS/PVA-PD-FeO NPs (0.01%) sponge would be recommended for diabetic wound dressing after a detailed in vivo evaluation.

show abstract

An overview on the role of bioactive α-glucosidase inhibitors in ameliorating diabetic complications

Cited by 253 publications

References 119 publications

Role of Postbiotics in Diabetes Mellitus: Current Knowledge and Future Perspectives

Role of Postbiotics in Diabetes Mellitus: Current Knowledge and Future Perspectives

Discovery of New α-Glucosidase Inhibitors: Structure-Based Virtual Screening and Biological Evaluation

Antimicrobial and Wound Healing Properties of FeO Fabricated Chitosan/PVA Nanocomposite Sponge

Contact Info

Product

Resources

About